Review Articles
Review Articles 1. Weiss, S., Winnacker, E.-L. and Famulok, M.: BSE und andere übertragbare spongiforme Enzephalopathien. 1995. Bioforum18, 8-12, 56-60 2. Edenhofer, F., Weiss, S., Winnacker, E.-L. and Famulok, M. Chemistry and molecular biology of transmissible spongiform encephalopathies. 1997. Angew.Chem. Int. Ed. Engl. 36, 1674-1694 3. Weiss, S. Prionen-Erkrankungen: Wie hoch ist das ?bertragungsrisiko (Prion diseases: How much is the risk of transmission). 1996. Pharmazeutische Zeitung 19, 11-26 4. Lasmézas, C.I., Deslys, J.P., Dormont, D. and Weiss, S. Une première étape dans l?identification de récepteurs cellulairs de la protéine du prion (Identifying cellular receptors for the prion protein). 1998. Médecine Sciences 14, 595-599 5. Rieger, R., Lasmézas, C. I., and Weiss, S. Role of the 37 kDa laminin receptor precursor in the life cycle of prions. 1999. Transfusion Clinique et Biologique 6, 7-16 6. Weiss, S. Erreger der neuen Art: Prionen. 2000. BIOforum 23, 577-579 7. Glockshuber, R., Kaaden, O.-R., Lücker, E. and Weiss, S. Vom Prion zu BSE/CJD– noch viele Fragen offen. BIOforum, 2001, 24, 101-103 8. Lasmézas, C.I. and Weiss, S. Prions, a novel class of infectious agents. BIOforum International, 2001, 5, 93-95 9. Gauczynski, S., Hundt, C., Leucht, C. and Weiss, S. Interaction of prion proteins with cell surface receptors, molecular chaperones and other molecules. 2001. Advances in Protein Chemistry, 57, 229-272 10. Leucht, C. und Weiss, S. Der Prion-Protein Rezeptor. 2002. Nova Acta Leopoldina, 87 (327) 39-54 11. Vana, K. and Weiss, S. BSE - die gebannte Gefahr? Epidemiologie, Therapie, Suszeptibilit?t und ?bertragbarkeit bei Prionenerkrankungen. 2006. BIOforum, 29 (1) 35-37 12. Rey, C., Zuber, C. and Weiss, S. Therapeutische Ans?tze zur Behandlung von Prionerkrankungen. 2006. Nova Acta Leopoldina, 94 (347) 129-144 5 13. Vana, K., Zuber, C., Nikles, D. and Weiss, S. Noval Aspects of Prions, their Receptor Molecules and innovative Approaches for TSE therapy. 2007. Cellular and Molecular Neurobiology, 27 (1) 107-128 14. Zuber, C., Ludewigs, H. and Weiss. S. Therapeutic Approaches targeting the prion receptor LRP/LR. 2007. Veterinary Microbiology, 123, 387-393 15. Ludewigs, H., Zuber, C., Vana, K., Nikles, D., Zerr, I. and Weiss, S. Therapeutic approaches for prion disorders. 2007. Expert Review of Anti-infective Therapy, 5 (4), 613-630 16. Heinemann, U., Weiss, S. and Zerr.I. Therapeutische Ans?tze zur Behandlung der Creutzfeldt-Jakob-Erkrankung. 2008. Medizinische Monatsschrift für Pharmazeuten, 31 (10), 378-384 17. Vana, K., Zuber, C., Pflanz, H., Kolodiejczak, D., Zemora, G., Bergmann, A.-K.and Weiss, S. LRP/LR as an alternative promising target in therapy of prion diseases, Alzheimer’s disease and cancer. 2009. Infectious Disorder Drug Targets 9(1), 69-80. 18. Mbazima, V. Da Costa Dias B., Omar, A., Jovanovick., and Weiss, S.F.T. Interactions between PrPc and other ligands with the 37-kDa/67-kDa laminin receptor. 2010. Frontiers in Biosciences, 15, 1150-1163. 19. Omar, A., Jovanovic, K., Da Costa Dias, B., Gonsalves, D., Moodley, K., Caveney, R., Mbazima, V., and Weiss, S.F.T. Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor. 2011. Expert Opin. Ther. Patents, 21, 35-53. 20. Da Costa Dias, B., Jovanovic, K., Weiss, S.F.T. Alimentary prion infections: Touchdown in the intestine. 2011. Prion, 5, 1- 4. 21. Da Costa Dias, B., Jovanovic, K., Gonsalves, D. and Weiss, S.F.T. 2011. Structural and mechanistic commonalities of amyloid-beta and the prion protein. Prion, 5 (3), 126-137. 22. Jovanovic, K.,Chetty, C.J., Khumalo, T., Da Costa Dias, B., Ferreira, E., Malindisa, S.T., Caveney, R., Letsolo, B. T. and Weiss, S.F.T. Novel patented therapeutic approaches targeting the 37kDa/67 kDa laminin receptor for treatment of Cancer and Alzheimer’s Disease. 2015. Expert Opinion on Therapeutic Patents, 25(5):567-582. 23. Vania, L., Morris, G., Otgaar, T.C., Bignoux, M.J., Bernert, M., Burns, J., Gabathuse, A., Singh, E., Ferreira, E. and Weiss, S.F.T. Patented therapeutic approaches targeting LRP/LR for cancer treatment. Expert Opinion on Therapeutic Patents (Journal ISSN: 1744-7674), 2019, Pages 987-1009 DOI: 10.1080/13543776.2019.1693543
|